mianserin has been researched along with Nausea in 22 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of the present paper was to evaluate the effectiveness of mirtazapine orally disintegrating tablets for nausea and sleep disturbance, which are common and distressing symptoms of cancer." | 9.13 | Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. ( Kim, JM; Kim, KM; Kim, KS; Kim, SW; Kim, YC; Shin, IS; Yang, SJ; Yoon, JS, 2008) |
| " This report presents the beneficial effect of low-dose mirtazapine added onto selective serotonin reuptake inhibitors in the treatment of the symptoms of severe nausea, insomnia and loss of appetite accompanying psychiatric disorders during pregnancy, which is an important problem in clinical practice." | 7.79 | Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases. ( Uguz, F, 2013) |
| "Mirtazapine and olanzapine are easy-to-use psychiatric drugs with potent antinausea effects." | 7.74 | Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. ( Foley, KF; Kast, RE, 2007) |
| "The antagonism of 5-HT3 receptor by mirtazapine results in an antiemetic effect, suggesting that mirtazapine could be considered a successful antiemetic agent in patients suffering from severe nausea and vomiting." | 7.73 | Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting. ( Pae, CU, 2006) |
| "Mirtazapine is an antidepressant that has a receptor-binding profile that may suit it for use in controlling the nausea and insomnia of highly emetic cancer chemotherapy." | 7.71 | Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. ( Kast, RE, 2001) |
| "Mirtazapine is a noradrenergic and specific serotonergic antidepressant(NaSSA)." | 6.74 | [Efficacy of mirtazapine for appetite loss and nausea of the cancer patient--from clinical experience in Memorial Sloan-Kettering Cancer Center]. ( Ito, T; Okubo, Y; Roth, A, 2009) |
| "Mirtazapine is an antidepressant with a mechanism that involves activating serotonin (5-HT1) receptors." | 6.47 | Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature. ( Huang, KC; Lee, WK; Li, TC; Shiah, IS; Sun, CJ; Tzang, RF, 2011) |
| "Mirtazapine is a new antidepressant called noradrenergic and specific serotonergic antidepressant(NaSSA)and blocks 5-HT3 receptors to improve nausea." | 5.38 | [Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy]. ( Imai, E; Ito, T; Nishimura, D; Shibahara, H; Uematsu, N, 2012) |
| "The purpose of the present paper was to evaluate the effectiveness of mirtazapine orally disintegrating tablets for nausea and sleep disturbance, which are common and distressing symptoms of cancer." | 5.13 | Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. ( Kim, JM; Kim, KM; Kim, KS; Kim, SW; Kim, YC; Shin, IS; Yang, SJ; Yoon, JS, 2008) |
| "Primary care patients with a major depressive disorder and 17-item Hamilton Rating Scale for Depression (17-HAM-D) score >18 were randomized to 24 weeks of treatment with mirtazapine 30-45 mg/day (n=99) or paroxetine 20-30 mg/day (n=98)." | 5.10 | A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. ( Angus, M; Crawford, GM; Hamilton, L; Wade, A; Wilson, R, 2003) |
| " This report presents the beneficial effect of low-dose mirtazapine added onto selective serotonin reuptake inhibitors in the treatment of the symptoms of severe nausea, insomnia and loss of appetite accompanying psychiatric disorders during pregnancy, which is an important problem in clinical practice." | 3.79 | Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases. ( Uguz, F, 2013) |
| "Mirtazapine and olanzapine are easy-to-use psychiatric drugs with potent antinausea effects." | 3.74 | Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. ( Foley, KF; Kast, RE, 2007) |
| "The antagonism of 5-HT3 receptor by mirtazapine results in an antiemetic effect, suggesting that mirtazapine could be considered a successful antiemetic agent in patients suffering from severe nausea and vomiting." | 3.73 | Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting. ( Pae, CU, 2006) |
| "Mirtazapine is an antidepressant that has a receptor-binding profile that may suit it for use in controlling the nausea and insomnia of highly emetic cancer chemotherapy." | 3.71 | Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. ( Kast, RE, 2001) |
| "Mirtazapine is a noradrenergic and specific serotonergic antidepressant(NaSSA)." | 2.74 | [Efficacy of mirtazapine for appetite loss and nausea of the cancer patient--from clinical experience in Memorial Sloan-Kettering Cancer Center]. ( Ito, T; Okubo, Y; Roth, A, 2009) |
| "Mirtazapine is a third-generation antidepressant with a dual mode of action." | 2.72 | Intravenous mirtazapine is safe and effective in the treatment of depressed inpatients. ( Egger, C; Eichberger, G; Hinterhuber, H; Hofmann, P; Kasper, S; Konstantinidis, A; Mühlbacher, M; Nickel, M; Nimmerrichter, A; Schubert, H; Stuppaeck, C, 2006) |
| "Mirtazapine is an antidepressant with a mechanism that involves activating serotonin (5-HT1) receptors." | 2.47 | Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature. ( Huang, KC; Lee, WK; Li, TC; Shiah, IS; Sun, CJ; Tzang, RF, 2011) |
| " The rates for individual side effects with the serotonin selective reuptake inhibitors, nefazodone, and venlafaxine are presented and compared with the adverse event experience for mirtazapine." | 2.40 | Safety and tolerability of the new antidepressants. ( Nelson, JC, 1997) |
| "Mirtazapine was administered to 50 cancer patients with digestive symptoms in palliative care, and the data were retrospectively examined." | 1.40 | [Effectiveness of mirtazapine for digestive symptoms in palliative care - retrospective study of 50 cases]. ( Imai, E; Nishimura, D; Shibahara, H; Tokura, Y; Uematsu, N, 2014) |
| "Mirtazapine is a new antidepressant called noradrenergic and specific serotonergic antidepressant(NaSSA)and blocks 5-HT3 receptors to improve nausea." | 1.38 | [Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy]. ( Imai, E; Ito, T; Nishimura, D; Shibahara, H; Uematsu, N, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shibahara, H | 2 |
| Uematsu, N | 2 |
| Imai, E | 2 |
| Tokura, Y | 1 |
| Nishimura, D | 2 |
| Kundu, S | 1 |
| Rogal, S | 1 |
| Alam, A | 1 |
| Levinthal, DJ | 1 |
| Smith, JH | 1 |
| Otera, M | 1 |
| Machida, T | 2 |
| Abe, M | 1 |
| Ichie, M | 1 |
| Fukudo, S | 1 |
| Bondade, S | 1 |
| Basavaraju, V | 1 |
| Singh, N | 1 |
| Ito, T | 2 |
| Okubo, Y | 1 |
| Roth, A | 1 |
| Li, TC | 1 |
| Shiah, IS | 1 |
| Sun, CJ | 1 |
| Tzang, RF | 1 |
| Huang, KC | 1 |
| Lee, WK | 1 |
| Uguz, F | 1 |
| Wade, A | 1 |
| Crawford, GM | 1 |
| Angus, M | 1 |
| Wilson, R | 1 |
| Hamilton, L | 1 |
| Pallanti, S | 1 |
| Quercioli, L | 1 |
| Bruscoli, M | 1 |
| Caldis, EV | 1 |
| Gair, RD | 1 |
| Raji, MA | 1 |
| Mühlbacher, M | 1 |
| Konstantinidis, A | 1 |
| Kasper, S | 1 |
| Eichberger, G | 1 |
| Hinterhuber, H | 1 |
| Hofmann, P | 1 |
| Nimmerrichter, A | 1 |
| Schubert, H | 1 |
| Egger, C | 1 |
| Nickel, M | 1 |
| Stuppaeck, C | 1 |
| Pae, CU | 2 |
| Kast, RE | 2 |
| Foley, KF | 1 |
| Kim, SW | 1 |
| Shin, IS | 1 |
| Kim, JM | 1 |
| Kim, YC | 1 |
| Kim, KS | 1 |
| Kim, KM | 1 |
| Yang, SJ | 1 |
| Yoon, JS | 1 |
| Han, C | 1 |
| Lee, BH | 1 |
| Ko, YH | 1 |
| Masand, PS | 1 |
| Patkar, AA | 1 |
| Joe, SH | 1 |
| Jung, IK | 1 |
| Pedersen, L | 1 |
| Klysner, R | 1 |
| Nelson, JC | 1 |
| Wheatley, DP | 1 |
| van Moffaert, M | 1 |
| Timmerman, L | 1 |
| Kremer, CM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients[NCT02650544] | Phase 2 | 236 participants (Anticipated) | Interventional | 2015-12-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for mianserin and Nausea
| Article | Year |
|---|---|
Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Electroconvulsive Therapy; Fema | 2011 |
Safety and tolerability of the new antidepressants.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressiv | 1997 |
7 trials available for mianserin and Nausea
| Article | Year |
|---|---|
[Efficacy of mirtazapine for appetite loss and nausea of the cancer patient--from clinical experience in Memorial Sloan-Kettering Cancer Center].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Appetite; Appetite Stimulants; Female; Hospit | 2009 |
A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antidepress | 2003 |
Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
Topics: Adult; Age of Onset; Antidepressive Agents, Tricyclic; Citalopram; Comorbidity; Depressive Disorder; | 2004 |
Intravenous mirtazapine is safe and effective in the treatment of depressed inpatients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Fatigue; Fema | 2006 |
Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression.
Topics: Adjustment Disorders; Administration, Oral; Adult; Aged; Antidepressive Agents, Tricyclic; Depressiv | 2008 |
Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week prospective, open-label, randomized, parallel-group trial.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Diagnostic and Statistical Manual of Mental Disorders; | 2008 |
Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Administration | 1998 |
13 other studies available for mianserin and Nausea
| Article | Year |
|---|---|
[Effectiveness of mirtazapine for digestive symptoms in palliative care - retrospective study of 50 cases].
Topics: Adult; Aged; Aged, 80 and over; Feeding and Eating Disorders; Female; Humans; Male; Mianserin; Middl | 2014 |
Rapid improvement in post-infectious gastroparesis symptoms with mirtazapine.
Topics: Abdominal Pain; Adrenergic alpha-Antagonists; Adult; Antiemetics; Female; Gastric Emptying; Gastropa | 2014 |
Mirtazapine for new daily persistent headache-associated chronic nausea.
Topics: Chronic Disease; Female; Headache; Histamine H1 Antagonists; Humans; Mianserin; Middle Aged; Mirtaza | 2015 |
Pharmacological and psychosomatic treatments for an elderly patient with severe nausea and vomiting in reaction to postoperative stress.
Topics: Aged; Amoxapine; Anti-Anxiety Agents; Antidepressive Agents; Antiemetics; Benzodiazepines; Bromazepa | 2015 |
Use of mirtazapine in functional vomiting.
Topics: Adult; Antidepressive Agents, Tricyclic; Female; Humans; Mianserin; Mirtazapine; Nausea; Vomiting | 2016 |
[Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy].
Topics: Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Combinations; Histamine H1 Antago | 2012 |
Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases.
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Dose-Response Relationship, Drug; Feeding and E | 2013 |
Mirtazapine for treatment of nausea induced by selective serotonin reuptake inhibitors.
Topics: Depressive Disorder, Major; Female; Histamine H1 Antagonists; Humans; Mianserin; Middle Aged; Mirtaz | 2004 |
Management of chemotherapy-induced side-effects.
Topics: Antiemetics; Antineoplastic Agents; Histamine H1 Antagonists; Humans; Mianserin; Mirtazapine; Nausea | 2005 |
Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting.
Topics: Adult; Antiemetics; Depressive Disorder; Humans; Korea; Male; Mianserin; Mirtazapine; Nausea; Vomiti | 2006 |
Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects.
Topics: Antiemetics; Antineoplastic Agents; Benzodiazepines; Cachexia; Humans; Mianserin; Mirtazapine; Nause | 2007 |
Antagonism of selective serotonin reuptake inhibitor-induced nausea by mirtazapine.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder; Female; | 1997 |
Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy.
Topics: Antidepressive Agents, Tricyclic; Antineoplastic Agents; Humans; Mianserin; Mirtazapine; Nausea; Sle | 2001 |